• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Elelyso (taliglucerase alfa) for injection, for intravenous use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

August 2014

Summary View

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis
  • Serious hypersensitivity reactions, including anaphylaxis, have occurred in some patients treated with Elelyso. In clinical trials, 2 of 72 (2.8%) patients treated with Elelyso experienced signs and symptoms consistent with anaphylaxis. Signs and symptoms of these patients included urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, and dizziness. These reactions occurred during Elelyso infusion.
  • In clinical trials with Elelyso, 21 of 72 (29%) patients experienced hypersensitivity reactions, including anaphylaxis. Signs and symptoms of hypersensitivity reactions included pruritus, angioedema, flushing, erythema, rash, nausea, vomiting, cough, chest tightness, and throat irritation. These reactions have occurred up to 3 hours after the start of infusion.
  • Due to the potential for anaphylaxis, appropriate medical support should be readily available when Elelyso is administered. Observe patients closely for an appropriate period of time after administration of Elelyso, taking into account the time to onset of anaphylaxis seen in clinical trials. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur. If anaphylaxis occurs, Elelyso should be immediately discontinued, and appropriate medical treatment should be initiated.
  • Management of hypersensitivity reactions should be based on the severity of the reaction and include slowing or temporary interruption of the infusion and/or administration of antihistamines, antipyretics, and/or corticosteroids for mild reactions. Pretreatment with antihistamines and/or corticosteroids may prevent subsequent hypersensitivity reactions. Patients were not routinely premedicated prior to infusion of Elelyso during clinical studies. If severe hypersensitivity reactions occur, immediately stop the infusion of Elelyso and initiate appropriate treatment.
  • Consider the risks and benefits of re-administering Elelyso in patients who have experienced a severe reaction associated with Elelyso. Caution should be exercised upon rechallenge, and appropriate medical support should be readily available.

ADVERSE REACTIONS

Postmarketing Experience
  • *revised to reflect the addition of text related to the occurrence of anaphylaxis related events as a postmarketing event*
 
-